Pfizer-BioNTech seek US approval of second Covid booster for 65+
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
  • Epaper
  • More
    • Subscribe
    • COVID-19
    • Bangladesh
    • Splash
    • Videos
    • Games
    • Long Read
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard

Friday
July 01, 2022

Sign In
Subscribe
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
  • Epaper
  • More
    • Subscribe
    • COVID-19
    • Bangladesh
    • Splash
    • Videos
    • Games
    • Long Read
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
FRIDAY, JULY 01, 2022
Pfizer-BioNTech seek US approval of second Covid booster for 65+

Coronavirus chronicle

BSS/AFP
16 March, 2022, 11:30 am
Last modified: 16 March, 2022, 12:14 pm

Related News

  • Bhutan to welcome tourists 'who can spend' for first time since Covid
  • Fever spread: Is it seasonal fever or Covid?
  • As fever spreads, doctors recommend rigorous Covid, dengue testing
  • 2,241 cases reported in 24 hours
  • US medical experts call for Omicron-specific Covid boosters

Pfizer-BioNTech seek US approval of second Covid booster for 65+

BSS/AFP
16 March, 2022, 11:30 am
Last modified: 16 March, 2022, 12:14 pm
Photo: Collected
Photo: Collected

Pfizer and BioNTech announced Tuesday they had formally asked the United States drug regulator for emergency approval of a second booster shot of their Covid vaccine for people aged 65 and older.

The companies said in a press statement that their request is based off two Israeli studies that show "an additional mRNA booster increases immunogenicity and lowers rates of confirmed infections and severe illness."

Most countries' case-levels have significantly declined from record levels during the Omicron wave, though multiple countries have seen levels plateau or start to tick up as they lift restrictions, and protection from prior doses begins to fade.

The first Israeli study cited by Pfizer and BioNTech showed that "rates of confirmed infections were 2 times lower and rates of severe illness were 4 times lower among individuals who received an additional booster dose," compared to those who only had one.

The analysis was limited to people 60 years and older who received their second booster four months after their first.

The second study -- an analysis of Israeli healthcare workers 18 years and older -- showed that antibody levels in those who received a second booster were significantly higher than those who did not.

"The study also revealed no new safety concerns in individuals who received an additional booster dose of the vaccine," said the companies.

Since the initial regimen of the Pfizer-BioNTech vaccine is two doses, a second booster would be most individuals' fourth jab.

Recent studies have offered evidence that while a third mRNA vaccine dose raises antibody levels above those of the initial regimen, a fourth dose only returns individuals' levels to that same highly-elevated level.

Several European countries, as well as Israel, have already approved second boosters for older and immunocompromised populations, who are most at-risk for severe disease.

Top News

Second Covid-19 booster dose / Covid-19 Booster Shots / Covid / Covid -19 / Pfizer coronavirus vaccine / Pfizer Covid-19 Vaccine

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • BB bids farewell to easy money policy to tame inflation
    BB bids farewell to easy money policy to tame inflation
  • Economist Zahid Hussain. Illustration: TBS
    Typical monetary steps cannot tame inflation
  • Ahsan H Mansur. TBS Sketch
    It won’t be able to rein in inflation

MOST VIEWED

  • Test tubes are seen in front of displayed Pfizer and Biontech logos in this illustration taken, May 21, 2021. Reuters: llustration
    BioNTech, Pfizer to start testing universal vaccine for coronaviruses
  • A woman holds a small bottle labelled with a "Coronavirus COVID-19 Vaccine" sticker and a medical syringe in this illustration taken October 30, 2020. REUTERS/Dado Ruvic/File Photo
    S Korea approves first domestically developed Covid vaccine
  • Photo: Collected
    US medical experts call for Omicron-specific Covid boosters
  • David E Adler. Sketch: TBS
    Who managed Covid-19 best, and why?
  • People line up at a nucleic acid testing station, following the coronavirus disease (COVID-19) outbreak, in Beijing, China, June 16, 2022. REUTERS/Thomas Peter/File Photo
    China slashes Covid quarantine time for international travellers
  • Covid-19 deaths were reported from Gorakhpur, Jalaun, Bulandshahr, Kannauj, Sonbhadra, Gonda, Bhadohi, Basti, Kushinagar and Mau (HT Photo)
    India sees 45% jump in a day with 17,073 new Covid cases

Related News

  • Bhutan to welcome tourists 'who can spend' for first time since Covid
  • Fever spread: Is it seasonal fever or Covid?
  • As fever spreads, doctors recommend rigorous Covid, dengue testing
  • 2,241 cases reported in 24 hours
  • US medical experts call for Omicron-specific Covid boosters

Features

Bangladesh ranks among the top ten countries whose citizens have sought asylum in Cyprus. Photo: Arafatul Islam/DW

How Bangladeshi migrants end up in Cyprus

13h | Panorama
Dr M Mushtuq Husain. Sketch: TBS

'We did not face an extreme crisis with Omicron. But this wave is spreading faster'

16h | Panorama
Luxury Houseboat owners  distributed food, provided medical assistance, and shelter to the flood victims, till the flood waters receded Photo: Masum Billah

The first responders: How luxury houseboats became rescue centres for flood victims

17h | Panorama
Mahathir accused financial titans of seeking to reverse decades of economic development that propelled tens of millions into the middle class. Photo: Bloomberg

George Soros, Mahathir and the legacy of 1997

1d | Panorama

More Videos from TBS

Shuttle train at CU: More than a mere transport

Shuttle train at CU: More than a mere transport

4h | Videos
Dhaka ranks as costliest city again in South Asia for expatriates

Dhaka ranks as costliest city again in South Asia for expatriates

5h | Videos
Kremlin hints solution to Ukraine war

Kremlin hints solution to Ukraine war

7h | Videos
Fever spread: Is it seasonal fever or Covid?

Fever spread: Is it seasonal fever or Covid?

7h | Videos

Most Read

1
Padma Bridge from satellite. Photo: Screengrab
Bangladesh

Padma Bridge from satellite 

2
Meet the man behind 'Azke amar mon balo nei'
Splash

Meet the man behind 'Azke amar mon balo nei'

3
Photo: TBS
Bangladesh

Motorcycles banned on Padma Bridge 

4
Photo: Collected
Economy

Tech startup ShopUp bags $65m in Series B4 funding

5
Photo: Courtesy
Corporates

Gree AC being used in all parts of Padma Bridge project

6
World Bank to give Bangladesh $18b IDA loans in next five years
Economy

World Bank to give Bangladesh $18b IDA loans in next five years

EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2022
The Business Standard All rights reserved
Technical Partner: RSI Lab
BENEATH THE SURFACE
Workers unload sacks of paddy at the BOC Ghat paddy market on the bank of the Meghna River in Brahmanbaria’s Ashuganj, the largest paddy market in the eastern part of the country. This century-old market sells paddies worth Tk5-6 crore a day during the peak season. PHOTO: RAJIB DHAR

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net